Back مضاد الصفيحات Arabic Antiagregant plaquetari Catalan Thrombozytenaggregationshemmer German Antiagregante plaquetario Spanish داروهای ضد پلاکت Persian Antiagrégant French Antiagregante plaquetario Galician נוגד טסיות HE Antiplatelet ID Farmaci antiaggreganti Italian
An antiplatelet drug (antiaggregant), also known as a platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that decrease platelet aggregation[1] and inhibit thrombus formation. They are effective in the arterial circulation where classical Vitamin K antagonist anticoagulants have minimal effect.[2]
Antiplatelet drugs are widely used in primary and secondary prevention of thrombotic disease, especially myocardial infarction and ischemic stroke.[1]
Antiplatelet therapy with one or more of these drugs decreases the ability of blood clots to form by interfering with the platelet activation process in primary hemostasis. Antiplatelet drugs can reversibly or irreversibly inhibit the process involved in platelet activation resulting in decreased tendency of platelets to adhere to one another and to damaged blood vessels' endothelium.[3]
- ^ a b Born G, Patrono C (January 2006). "Antiplatelet drugs". British Journal of Pharmacology. 147 Suppl 1 (Suppl 1): S241 – S251. doi:10.1038/sj.bjp.0706401. PMC 1760725. PMID 16402110.
- ^ García-Ropero Á, Vargas-Delgado AP, Santos-Gallego CG, Badimon JJ (April 2020). "Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?". Journal of Cardiovascular Pharmacology. 75 (4): 269–275. doi:10.1097/FJC.0000000000000795. PMID 31923049. S2CID 210149420.
- ^ "SDCEP Anticoagulants and Antiplatelets" (PDF). Archived from the original (PDF) on 2017-03-28. Retrieved 2016-03-09.